Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib
Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib.<br /><br /><br /><br />BACK...
Author: Annual-Meeting
Added: 06/07/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Study